SML1594
西仑吉肽三氟乙酸盐
≥95% (HPLC), vascular targeting agent, powder
别名:
2,2,2-三氟乙酸, EMD 121974, NSC 707544, c(RGDF(NMe)V), 环(L-精氨酰甘氨酰-L-a-天冬氨酰-D-苯丙氨酰-N-甲基-L-缬氨酰), 2,2,2-三氟乙酸
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C27H40N8O7 · xC2HF3O2
化学文摘社编号:
分子量:
588.66 (free base basis)
UNSPSC Code:
12352106
NACRES:
NA.77
产品名称
西仑吉肽三氟乙酸盐, ≥95% (HPLC)
Quality Level
assay
≥95% (HPLC)
form
powder
color
white to beige
solubility
H2O: 20 mg/mL, clear
storage temp.
−20°C
SMILES string
N1([C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](C1=O)Cc2ccccc2)CC(=O)O)CCCN\C(=N\[H])\N)C(C)C)C
InChI
1S/C27H40N8O7/c1-15(2)22-25(41)33-17(10-7-11-30-27(28)29)23(39)31-14-20(36)32-18(13-21(37)38)24(40)34-19(26(42)35(22)3)12-16-8-5-4-6-9-16/h4-6,8-9,15,17-19,22H,7,10-14H2,1-3H3,(H,31,39)(H,32,36)(H,33,41)(H,34,40)(H,37,38)(H4,28,29,30)/t17-,18-,19+,22-/m0/s1
InChI key
AMLYAMJWYAIXIA-VWNVYAMZSA-N
Application
西仑吉肽(cilengitide)的三氟乙酸盐已用作整合素αvβ5的抑制剂。
Biochem/physiol Actions
对多形性胶质母细胞瘤具有抗肿瘤活性。整合素是α和β链的异二聚体，作为跨膜受体负责细胞与细胞、细胞与胞外基质作用。可调控肿瘤血管生成、侵袭和迁移。
西仑吉肽(cilengitide)是可充当整合素拮抗剂的血管靶向制剂(VTA)。
西仑吉肽(cilengitide)是可充当整合素拮抗剂的血管靶向制剂(VTA)。 西仑吉肽是一种含Arg-Gly-Glu(RGD)的环状五肽，可选择性抑制整合素的αvβ3和αvβ5。
存储类别
11 - Combustible Solids
wgk
WGK 3
法规信息
常规特殊物品
此项目有
Activation of Hepatic Stellate Cells During Liver Carcinogenesis Requires Fibrinogen/Integrin αvβ5 in Zebrafish.
Yan C, et al.
Neoplasia, 20(5), 533-542 (2018)
David A Reardon et al.
Expert opinion on investigational drugs, 17(8), 1225-1235 (2008-07-12)
Glioblastoma multiforme (GBM), a highly invasive and vascular cancer, responds poorly to conventional cytotoxic therapy. Integrins, widely expressed in GBM and tumor vasculature, mediate cell survival, migration and angiogenesis. Cilengitide is a potent alphavbeta3 and alphavbeta5 integrin inhibitor. To summarize
David A Reardon et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26(34), 5610-5617 (2008-11-05)
Cilengitide, an inhibitor of alphavbeta3 and alphavbeta5 integrin receptors, demonstrated minimal toxicity and durable activity across a wide range of doses administered to adults with recurrent glioblastoma multiforme (GBM) in a prior phase I study. The current multicenter phase II
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| SML1594-25MG | 04061833213537 |
| SML1594-5MG | 04061833213544 |